Thyroid hormones play a role in the regulation of @entity442 ) and @entity2301 ( @entity2301 ) expression, and both @entity442 and IGFBPs have been shown to be related to the function and growth of the thyroid. Our aim was to evaluate serum concentrations of @entity442 , @entity10116 , and @entity2301 in @entity1 with @entity1374 before and after normalization of thyroid function. The study was performed in 86 @entity1 with @entity1374 (43 @entity1378 and 43 @entity1375 @entity1 ) and 17 euthyroid subjects. Serum @entity2124 ( @entity2124 ), insulin, @entity442 , @entity10116 , and @entity2301 were measured in all @entity1 before and after normalizing serum @entity6145 concentrations. @entity1378 @entity1 showed @entity442 (198.8 +/- 17.0 microg/L) and @entity2301 levels (4.2 +/- 0.2 mg/L) similar to those found in the control group (217.9 +/- 20.3 microg/L and 4.2 +/- 0.3 mg/L, respectively). After therapy these levels significantly decreased to 156.6 + 11.1 microg/L (p < 0.01) and 3.3 +/- 0.1 mg/L (p < 0.001), respectively. @entity10116 concentrations were clearly higher than those found in controls (22.7+/- 2.6 vs. 5.7 +/- 1.5 microg/L, p < 0.001) and exhibited a significant reduction after therapy for @entity1374 (11.0 +/- 1.7 microg/L, p < 0.001). @entity1 with @entity1375 showed serum concentrations of @entity442 (161.5 +/- 13.1 microg/L, p < 0.05) and @entity2301 (3.2 +/- 0.3 microg/L, p < 0.05) significantly lower than those found in healthy volunteers. However, replacement therapy with @entity1955 did not induce any significant modification of these concentrations (152.6 +/- 10.6 microg/L and 3.2 +/- 0.2 mg/L, respectively). Similarly, @entity1 with @entity1374 exhibited raised levels of @entity10116 (15.5 +/- 0.9 microg/L, p < 0.05 vs. control group) that were significantly decreased after therapy (8.8 +/- 1.4 microg/L, p < 0.01). The results of the present study show that thyroid status affects @entity2124 /IGF axis. @entity1375 is associated with significant reductions of @entity442 and @entity2301 , and @entity10116 is elevated in both @entity1375 and @entity1378 .

Serum XXXX , and @entity2301 concentrations in @entity1 with @entity1374 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['Hypothyroidism', 'hypothyroidism', 'hypothyroid'] @entity2301 :: ('3486', 'Gene') :: ['IGFBP-3', 'insulin-like growth factor-binding protein-3'] @entity442 :: ('3479', 'Gene') :: ['IGF-1', 'insulin-like growth factor type 1 (IGF-1'] @entity10116 :: ('3484', 'Gene') :: ['IGFBP-1'] @entity1955 :: ('MESH:D013974', 'Chemical') :: ['levothyroxine'] @entity1378 :: ('MESH:D006980', 'Disease') :: ['hyperthyroidism', 'Hyperthyroid', 'hyperthyroid'] @entity2124 :: ('2688', 'Gene') :: ['GH', 'growth hormone'] @entity6145 :: ('CHEBI:60311', 'Chemical') :: ['thyroid hormone'] @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid dysfunction', 'thyroid hyperfunction', 'thyroid hypofunction']
@entity10116 :: (3484,Gene) :: ['insulin-like growth factor type 1, insulin-like growth factor-binding protein-1']
